Managed care interventions for improving outcomes in acute heart failure syndromes.

Acute heart failure syndromes (AHFS) are characterized by a gradual or rapid progression of the signs and symptoms of heart failure (HF), resulting in a need for urgent therapy. Patients with AHFS comprise approximately 20% of all HF patients and represent the most severely ill and undermanaged subpopulation of patients with HF. Despite the rising prevalence and costs associated with AHFS, the disease remains largely undermanaged, partially as a result of a failure to initiate treatment with proven therapies, such as beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers, during hospitalization or soon after discharge. Although professional organizations have been striving to improve the state of care for AHFS by providing at least some level of consensus and evidence-based treatment recommendations, the gap between the clinical evidence and actual practice is growing. Appropriate disease assessment, followed by the implementation of life-saving therapies, is the key to improving outcomes. Managed care initiatives, such as improved quality measures, disease management programs, patient education efforts, hospital discharge checklists, and pharmacy-led interventions to enhance medication compliance, provide potential solutions for combating the alarming rise of morbidity, mortality, and costs associated with this disease.

[1]  G. Fonarow,et al.  Influence of coronary artery disease and coronary revascularization status on outcomes in patients with acute heart failure syndromes: A report from OPTIMIZE‐HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) * , 2008, European journal of heart failure.

[2]  C. O'connor,et al.  Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). , 2008, American heart journal.

[3]  K. Swedberg,et al.  Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. , 2008, JAMA.

[4]  R. Califf,et al.  Admission or Changes in Renal Function During Hospitalization for Worsening Heart Failure Predict Postdischarge Survival: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) , 2008, Circulation. Heart failure.

[5]  David D. Shin,et al.  Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. , 2007, Archives of internal medicine.

[6]  G. Fonarow,et al.  Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. , 2007, European heart journal.

[7]  K. Swedberg,et al.  Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.

[8]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[9]  M. Guglin,et al.  Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. , 2007, Journal of the American College of Cardiology.

[10]  David D. Shin,et al.  Review of current and investigational pharmacologic agents for acute heart failure syndromes. , 2007, The American journal of cardiology.

[11]  Nancy M Albert,et al.  Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. , 2006, JAMA.

[12]  J. Rouleau,et al.  Navigating the Crossroads of Coronary Artery Disease and Heart Failure , 2006, Circulation.

[13]  Carol R Horowitz,et al.  Effects of Nurse Management on the Quality of Heart Failure Care in Minority Communities , 2006, Annals of Internal Medicine.

[14]  Luigi Tavazzi,et al.  Acute Heart Failure Syndromes: Current State and Framework for Future Research , 2005, Circulation.

[15]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[16]  Harlan M Krumholz,et al.  ACC/AHA Clinical Performance Measures for Adults with Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society , 2005, Circulation.

[17]  A. Mebazaa,et al.  The challenge of acute heart failure syndromes. , 2005, The American journal of cardiology.

[18]  M. Nieminen Pharmacological options for acute heart failure syndromes: current treatments and unmet needs , 2005 .

[19]  W John Boscardin,et al.  Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. , 2005, JAMA.

[20]  K. Adams,et al.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.

[21]  Christopher M O'Connor,et al.  Risk stratification after hospitalization for decompensated heart failure. , 2004, Journal of cardiac failure.

[22]  Holly Rimmasch,et al.  Improvements in 1-Year Cardiovascular Clinical Outcomes Associated with a Hospital-Based Discharge Medication Program , 2004, Annals of Internal Medicine.

[23]  Kamyar Kalantar-Zadeh,et al.  Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. , 2004, Journal of the American College of Cardiology.

[24]  M. Gheorghiade,et al.  Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure: Results From a Double-Blind, Randomized Trial , 2003, Circulation.

[25]  T. Speroff,et al.  Decompensated heart failure: symptoms, patterns of onset, and contributing factors. , 2003, The American journal of medicine.

[26]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[27]  R. Maestri,et al.  Cost/utility ratio in chronic heart failure: comparison between heart failure management program delivered by day-hospital and usual care , 2002 .

[28]  A. Gawlinski,et al.  Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). , 2001, The American journal of cardiology.

[29]  S. Yusuf,et al.  Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. , 1994, Journal of the American College of Cardiology.

[30]  Abraham Wt,et al.  Body fluid volume regulation in health and disease. , 1994 .

[31]  M. Packer,et al.  Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. , 1984, The New England journal of medicine.